Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Income from Continuing Operations (2022 - 2025)

Corvus Pharmaceuticals has reported Income from Continuing Operations over the past 4 years, most recently at 11614000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 11614000.0 for Q4 2025, down 16.85% from a year ago — trailing twelve months through Dec 2025 was 13325000.0 (up 77.45% YoY), and the annual figure for FY2025 was 13325000.0, up 77.45%.
  • Income from Continuing Operations for Q4 2025 was 11614000.0 at Corvus Pharmaceuticals, down from 9834000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CRVS hit a ceiling of 15732000.0 in Q1 2025 and a floor of 39535000.0 in Q3 2024.
  • Median Income from Continuing Operations over the past 4 years was 6577500.0 (2022), compared with a mean of 7920687.5.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 669.91% in 2024 and later skyrocketed 364.98% in 2025.
  • Corvus Pharmaceuticals' Income from Continuing Operations stood at 5666000.0 in 2022, then rose by 7.36% to 5249000.0 in 2023, then crashed by 89.35% to 9939000.0 in 2024, then decreased by 16.85% to 11614000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 11614000.0 (Q4 2025), 9834000.0 (Q3 2025), and 7609000.0 (Q2 2025) per Business Quant data.